Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

amphetamine salts including but not limited to the ability to get sufficient quota from the US Drug Enforcement Agency ('DEA'); - technological advances (including the approval of new competing products for ADHD treatments); - changes in reimbursement policies of third-party payers; - government action/intervention; - marketing or pricing actions by competitors; - public opinion towards ADHD treatments; - any change in the label or other such regulatory intervention; - product liability claims; and - changes in prescription-writing practices.

Any decrease in the sales of 3TC could significantly reduce earnings

The Group receives royalties from GlaxoSmithKline ('GSK') on the worldwide sales of 3TC. In 2008, the Group's royalty income relating to 3TC sales was $140.2 million (2007: $145.3 million). This royalty income stream generates a larger proportion of net income relative to the Group's own product sales as there are minimal costs associated with its generation.

Any factors that decrease sales of 3TC by GSK could significantly reduce the Group's earnings. These include:

    - development and marketing of competitive pharmaceuticals,
      including generic versions;

    - loss of patent protection or ability of competitors to
      challenge or circumvent patents;

    - reduction in the production of 3TC;

    - technological advances;

    - government action/intervention;

    - marketing or pricing actions by GSK's competitors;

    - any change in the label or other such regulatory intervention;

    - public opinion towards AIDS treatments; and

    - product liability claims.

The failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payers in a timely manner for certain of the Group's products and parallel importation may impact future re
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... 10, 2014 On July 9 ... , presented Russia,s first national ... The Company is developing a unique project called ... develops a number of innovative drugs based on monoclonal ... ceremony took place at the International Exhibition "Innoprom 2014" ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2
... , , , , , ... -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or ... and medical nutrients addressing a variety of diseases and ... flagship Xin Aoxing,Oleanolic Acid ("Xin Aoxing") Capsules for the ...
... , , ORLANDO, Fla., Dec. ... GNLK) a leading consumer genomics and biotechnology company ( www.genelinkbio.com ... Macdonald as its interim Chief Executive Officer, effective December 28, ... leader with more than 25 years of experience building high ...
... , , , , , , , , ... ( SVA),a leading provider of biopharmaceutical products in China, announced today,that ... (SFDA) to commence a human clinical trial for its vaccine,against human ... This is the first clinical trial application for HFMD vaccine,submitted in ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai 2Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai 3David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 2David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 3David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 4Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 2Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 3Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 4
(Date:7/11/2014)... A new report from the Wildlife Conservation Society ... only help economically valuable species such as lobster, ... also help re-colonize nearby reef areas. , The ... a systematic review of research literature from no-take ... by Dr. Craig Dahlgren, a recognized expert in ...
(Date:7/11/2014)... a new professorship in tissue engineering to promote ... Engineering and the Marine Biological Laboratory, supported by ... Eugene Bell Foundation., The Eugene Bell Professorship in ... Molecular Engineering. That endowed chair holder also will ... Bell Center for Regenerative Biology and Tissue Engineering, ...
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2New professorship in tissue engineering links molecular engineering, marine biology 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... Oct. 17, 2011 Dr. Randal Halfmann, a ... of 10 investigators selected for the first National Institutes ... new program allows creative early-career scientists to leapfrog the ... independent investigations. The charter group of awardees will share ...
... Oct. 17, 2011 Aware, Inc. (Nasdaq: ... software, today announced the development of the Next-Generation Universal ... agencies of the U.S. Department of Justice. Universal ABS ... BioComponents™ product family; a flexible, modular, COTS software framework ...
... Ga. Nearly all active people suffer ankle sprains at ... Georgia study suggests that the different ways people move their ... In the past, sports medicine therapists prescribed strengthening and ... The study by UGA kinesiology researchers, published in the early ...
Cached Biology News:UT Southwestern biochemist receives new NIH Early Independence Award 2Aware Develops Next-Generation Biometric Enrollment Application for Department of Justice 2Aware Develops Next-Generation Biometric Enrollment Application for Department of Justice 3Aware Develops Next-Generation Biometric Enrollment Application for Department of Justice 4UGA study suggests key to avoiding ankle re-injury may be in the hips and knees 2
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
... Sight DS-L2 imaging controller is a successor ... and allows users to comfortably observe, record ... controller features an 8.4 inch LCD (XGA) ... of Nikon cameras including the DS-Fi1 , ...
... is a premium quality recombinant form of ... is suitable for a wide range of ... and reproducible performance, each preparation is extensively ... assays. NovaTaq DNA Polymerase possesses an integral ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Biology Products: